Androgen deprivation, either by interfering with synthesis of testosterone or by blocking androgen receptor (AR) activity with AR antagonists such as bicalutamide or enzalutamide, is still the standard therapy of metastasizing prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.